title: Development and characterization of embelin-loaded nanolipid carriers for brain targeting.
abstract: The objective of present work was to enquire the potential use of embelin-loaded nanolipid carriers for brain targeting. The average particle size and polydispersity index (PDI) of optimized formulation (F19) were found to be 152 ± 19.7 nm and 0.143 ± 0.023, respectively. Nanolipid carrier (NLC) was also significantly attenuated pentylenetetrazole (PTZ)-induced biochemical parameters in comparison to plain embelin that results in an increase in the level of malondialdehyde (MDA), nitrite, and reduction in the level of glutathione. From the results, it was concluded that embelin-NLCs developed as a beneficial carrier to achieve sustained release and brain targeting through nasal route.
authors.affiliation: a Department of Pharmaceutics , I.S.F. College of Pharmacy , GT Road , Moga , Punjab , India.
authors.forename: Nancy
authors.initials: N
authors.lastname: Sharma
authors.affiliation: b Department of Quality Assurance , I.S.F. College of Pharmacy , GT Road , Moga , Punjab , India.
authors.forename: Saurav
authors.initials: S
authors.lastname: Bhandari
authors.affiliation: c Department of Pharmacology , I.S.F. College of Pharmacy , GT Road , Moga , Punjab , India.
authors.forename: Rahul
authors.initials: R
authors.lastname: Deshmukh
authors.affiliation: d Department of Pharmaceutics , Bhagyoday Tirth Pharmacy College , Sagar (MP) , India.
authors.forename: Awesh K
authors.initials: AK
authors.lastname: Yadav
authors.affiliation: a Department of Pharmaceutics , I.S.F. College of Pharmacy , GT Road , Moga , Punjab , India.
authors.forename: Neeraj
authors.initials: N
authors.lastname: Mishra
mesh_terms: D000281:Administration, Intranasal; D000818:Animals; D016227:Benzoquinones / Q000097:blood / Q000493:pharmacokinetics* / Q000494:pharmacology; D001921:Brain / Q000187:drug effects* / Q000378:metabolism; D003292:Convulsants / Q000037:antagonists & inhibitors / Q000494:pharmacology; D004337:Drug Carriers; D004339:Drug Compounding; D065546:Drug Liberation; D005260:Female; D005978:Glutathione / Q000819:agonists / Q000378:metabolism; D008297:Male; D008315:Malondialdehyde / Q000037:antagonists & inhibitors / Q000378:metabolism; D053758:Nanoparticles / Q000737:chemistry* / Q000378:metabolism; D009573:Nitrites / Q000037:antagonists & inhibitors / Q000378:metabolism; D010168:Palmitates / Q000737:chemistry*; D010316:Particle Size; D010433:Pentylenetetrazole / Q000037:antagonists & inhibitors / Q000494:pharmacology; D020442:Poloxamer / Q000737:chemistry; D051381:Rats; D017208:Rats, Wistar; D014018:Tissue Distribution
chemical_list: D016227:Benzoquinones; D003292:Convulsants; D004337:Drug Carriers; D009573:Nitrites; D010168:Palmitates; D020442:Poloxamer; D008315:Malondialdehyde; C006957:cetyl palmitate; D005978:Glutathione; C010945:embelin; D010433:Pentylenetetrazole
keywords: Embelin; epilepsy; intranasal delivery; nanolipid carrier; pentylenetetrazole